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Introduction
Heart failure is a highly lethal syndrome, the two most
common causes of mortality being sudden death and
pump failure. Ventricular arrhythmias underlie many of
the sudden deaths. Multiple lines of evidence implicate
downregulation of K channel expression, with atten-
dant delay of repolarization, in the pathogenesis of the
ventricular arrhythmias associated with cardiomyopa-
thy. K channel downregulation may initially be an adap-
tive response in the failing heart, given that prolonga-
tion of the action potential increases the time available
for excitation-contraction coupling during each cardiac
cycle. Gene therapy has been proposed as a therapeutic
strategy to reverse K channel downregulation; never-
theless, an obvious risk of such therapy is a decline of
the already compromised contractility of the failing
heart. Our early monogenic attempt to normalize
delayed repolarization in failing ventricular myocytes
via overexpression of a foreign K channel proved the
case in point (1). While overexpression of a noninacti-
vating K channel effectively abbreviated repolarization,
it adversely impacted excitation-contraction coupling
by causing reduced cell shortenings (Figure 1) (1).
We thus sought to develop a strategy to reverse the K
channel downregulation without depressing contractil-
ity. Bicistronic vectors enable the coexpression of two
genes driven by a single promoter. We designed such a
construct to coexpress the skeletal muscle calcium
ATPase isoform SERCA1 with the K channel Kir2.1. Pre-
vious studies have demonstrated the utility of SERCA
gene delivery in boosting cardiac contractility by increas-
ing calcium loading of the sarcoplasmic reticulum; here,
we chose to use the SERCA1 isoform given its usual
absence in the heart and its unique antigenicity (prop-
erties which facilitate the unambiguous documentation
of transgene expression), as well as its high turnover rate
relative to SERCA2 (2, 3). For the K channel, we selected
Kir2.1, which encodes a cardiac inward rectifier channel.
Kir2.1 is expected to abbreviate excitability by accelerat-
ing terminal repolarization (4). By itself, such an effect
might prove deleterious for pump function, but we
hypothesized that the addition of SERCA1 would offset
the loss of contractility due to abbreviation of the action
potential. The ideas were tested by expression of the dual
gene therapy vector in the ventricle, measuring end-
points both in isolated cells (action potentials, mem-
brane current, and calcium transients) and in vivo (elec-
trocardiograms and echocardiograms).
Methods
Plasmid construction and adenovirus preparation. The ade-
novirus shuttle vectors pAdEGI, pAdEGI-Kir2.1, and
pAdCGI-DBEcR have been described elsewhere (5, 6).
The coding sequence from rat SERCA1a (kindly sup-
plied by M. Periasamy, The Ohio State University,
Columbus, Ohio, USA) was cloned into the first posi-
tion of the adenovirus shuttle vector pAdEGI-Kir2.1 in
place of the enhanced green fluorescence protein
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(EGFP) sequence, to generate pAdSERCA1-Kir2.1. Ade-
novirus vectors were generated by Cre-lox recombina-
tion of purified ψ5 viral DNA and shuttle vector DNA
as described previously (5–7). The recombinant prod-
ucts were plaque-purified, expanded, and purified on
CsCl gradients yielding concentrations on the order of
1010 plaque-forming units (PFU) per milliliter.
Animals. Adult guinea pigs (220–260 g) underwent
direct intramyocardial adenovirus injection using a 30-
gauge needle as reported previously (6, 8, 9). For patch-
clamp experiments, a single site within the anterior wall
of the left ventricle was infiltrated under direct visuali-
zation three to five times with a total volume of 150 µl
of an adenovirus mixture containing 5 × 108 PFU
AdCGI-DBEcR and 5 × 108 PFU AdEGI (control group)
or 5 × 108 PFU AdCGI-DBEcR and 5 × 108 PFU AdE-
SERCA1-Kir2.1 (S-K group). For electrocardiogram
(ECG) recordings and ultrasound studies, the left ven-
tricle was injected in a more widespread manner at mul-
tiple sites (about ten sites, each site injected once) from
the base to the apex of the anterior, lateral, and posteri-
or wall, with a total volume of 220 µl of the same aden-
ovirus mixture, this time containing 8 × 108 PFU
AdCGI-DBEcR and 8 × 108 PFU AdEGI (control group)
or 8 × 108 PFU AdCGI-DBEcR and 8 × 108 PFU AdE-
SERCA1-Kir2.1 (S-K group). After the chest was closed,
animals were injected intraperitoneally with 40 mg of
the nonsteroidal ecdysone receptor agonist GS-E [N-(3-
methoxy-2-ethylbenzoyl)-N′-(3,5-dimethylbenzoyl)-N′-
tert-butylhydrazine; kindly provided by Rohm and Haas
Co., Spring House, Pennsylvania, USA], dissolved in 90
µl DMSO and 360 µl sesame oil.
Myocyte isolation and electrophysiology. Seventy-two
hours after myocardial injection, guinea pig left ven-
tricular myocytes were isolated as described previ-
ously (10, 11). These enzymatic dissociations typical-
ly yielded 50–70% viable myocytes. The yield of
infected myocytes, identifiable by their green fluo-
rescence (see below), was about 2% as judged by visu-
al assessments when cells were dispersed into the elec-
trophysiologic recording chamber. The low yield of
green viable myocytes was due to the limited efficien-
cy of gene transduction by direct cardiac injection of
adenovirus. Experiments were carried out using the
whole-cell patch-clamp technique (12) with an
Axopatch 200B amplifier (Axon Instruments Inc.,
Foster City, California, USA) while sampling at 10
kHz (for currents) or 2 kHz (for voltage recordings)
and filtering at 2 kHz. Pipettes had tip resistances of
2–4 MΩ when filled with the internal recording solu-
tion. The inward rectifier K currents (IK1) and calci-
um transients were recorded at room temperature
(∼21°C), while action potential (AP) recordings were
obtained at 37°C. APs were initiated by short depo-
larizing current pulses (2 ms, 200–600 pA) at 1 Hz. AP
duration (APD) was measured as the time from the
overshoot to 50% or 90% repolarization (APD50 or
APD90, respectively). A xenon arc lamp was used to
view green fluorescent protein (GFP) fluorescence at
488/530 nm (excitation/emission). Infected cells were
recognized by their obvious green fluorescence.
Although fluorescence was attributable to AdCGI-
DBEcR and not to AdESERCA1-Kir2.1 infection in
the case of the S-K group, it has been already shown
by our laboratory that coinfection of the receptor and
shuttle viruses is the rule rather than the exception
(9). Given that we have shown that adenovirus infec-
tion itself does not modify the electrophysiology of
guinea pig myocytes (9), patch-clamp experiments
performed in uninfected (non-green) left ventricular
myocytes isolated from AdESERCA1-Kir2.1–injected
animals, as well as in green cells from AdEGI-injected
hearts, were used as controls.
Cells were superfused with a physiological saline
solution containing (in mM): 138 NaCl, 5 KCl, 2 CaCl2,
10 glucose, 0.5 MgCl2, 10 HEPES; pH was adjusted to
7.4 with NaOH. The micropipette electrode solution
for IK1 recordings was composed of (in mM): 140 KCl,
4 MgATP, 5 EGTA, 1 MgCl2, 10 HEPES, pH adjusted to
7.4 with KOH, while the one used for AP recordings
contained (in mM): 130 K-glutamate, 10 KCl, 5
MgATP, 0.5 MgCl2, 10 NaCl, 10 HEPES, pH adjusted
to 7.2 with KOH. EGTA (5 mM) was added to the
pipette solution as indicated to record APs under high-
ly Ca-buffered conditions.
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Figure 1
Adverse effects of monogenic K channel overexpression on contrac-
tility. Action potentials (upper panels) and contractions (lower pan-
els) recorded (22°C) in failing canine myocytes infected with AdShK
and maintained in primary culture (1). Expression of ShK current
shortened action potentials but also markedly blunted contractions
(lower right panel). Prolonged action potentials and diminished K
currents are characteristic of myocytes isolated from failing canine
ventricles (18). This failing phenotype persists in primary culture (1).
Calcium transients. The K+ salt form of the Ca2+ indi-
cator Indo-1 (Molecular Probes Inc., Eugene , Ore-
gon, USA) was used to measure intracellular Ca2+ as
previously described (13). Briefly, Ca2+ transients
were elicited in isolated cardiomyocytes of the inject-
ed hearts in response to voltage steps (from –80 to 0
mV) at a frequency of 1 Hz. Indo-1 fluorescence was
excited at 365 nm with a xenon arc lamp and the
emissions at 405 nm and 495 nm were collected with
a two-channel photomultiplier tube (PMT) assembly
(ESP Associates, Toronto, Canada). Fluorescence was
digitized and stored simultaneously with the electro-
physiological signals and analyzed using custom-
written software (Ion View, written by B. O’Rourke).
Indo-1 405/495-nm emission ratio was calculated
after subtraction of cellular autofluorescence, which
was recorded before rupturing the cell-attached
patch. The internal pipette solution was composed of
(in mM): 130 K-glutamate, 9 KCl, 10 NaCl, 0.5
MgCl2, 5 MgATP, 10 HEPES, 0.08 Indo-1, pH adjust-
ed to 7.3 with KOH.
Western blots. The ectopic expression of SERCA1a pro-
tein in hearts injected with AdESERCA1-Kir2.1, and
the relative protein levels of SERCA2a and Kir2.1, were
indexed by the immunoblot technique. For this pur-
pose, crude homogenates of the left ventricle were pre-
pared. Equal amounts of protein extract from the dif-
ferent groups of animals (∼20 µg/lane) were subjected
to electrophoresis and the separated proteins were
transferred to nitrocellulose membranes (Novex
immunoblot kit; Invitrogen Corporation, Carlsbad,
California, USA). Blots were incubated with the appro-
priate mAb and in sequential steps with the corre-
sponding peroxidase-conjugated secondary antibody
(anti-mouse or anti-rabbit IgG; Amersham Biosciences
Inc., Uppsala, Sweeden). The enhanced chemilumines-
cent detection system (Amersham) was used for signal
detection. Relative protein level was determined by nor-
malization to the level of actin, which was also used as
an internal control. The following antibodies were
used: A52 (14) (monoclonal SERCA1a antibody, kind-
ly provided by D. MacLennan, University of Toronto,
Toronto, Ontario, Canada), MA3-910 (monoclonal
SERCA2a antibody; Affinity BioReagents Inc., Golden,
Colorado, USA), APC-026 (polyclonal anti-Kir2.1;
Alomone Laboratories Ltd., Jerusalem, Israel) , and 
AC-40 (monoclonal anti-actin; Sigma Chemical Co. St.
Louis, Missouri, USA).
Immunoblots were also performed to evaluate how
widespread SERCA1 expression was in animals that
underwent multiple-site injections. Hearts were
excised at 72 hours after viral injection and after ECG
and echocardiography recordings were performed.
Atria and all adjacent connective tissue were removed.
The right ventricle was cut into two pieces and the
left ventricle into six equal pieces. Homogenates of
each sample were prepared and Western blots per-
formed as described above using the monoclonal
SERCA1a antibody A52 (14).
ECGs. Surface ECGs were recorded immediately after
operation and 72 hours after intramyocardial injection
as previously described (9, 15). Guinea pigs were sedat-
ed with methoxyflurane, and needle electrodes were
placed under the skin. Electrode positions were opti-
mized to obtain maximal amplitude recordings,
enabling accurate measurements of QT intervals.
ECGs were simultaneously recorded from standard
lead II, and modified leads I and III. The positions of
the needle electrodes were marked on the guinea pigs’
skin after recording, to ensure exactly the same local-
ization 72 hours later.
Cardiac echocardiography. Measurements were made 72
hours after intramyocardial injection. Guinea pigs were
sedated with methoxyflurane and placed on a warming
pad. Echocardiography images were obtained with a 6-
to 15-MHz multifrequency probe using an Agilent
Sonos 5500 ultrasound machine (Agilent Technologies
Inc., Palo Alto, California, USA). Two-dimensional
imaging–directed M-mode measurements of left ven-
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Figure 2
SERCA protein expression. When an mAb against SERCA1a (A52;
ref. 14) was assayed, a specific band at about 100 kDa was observed
in samples from AdESERCA1-Kir2.1–injected hearts, while no signal
was detected in control heart samples. Interestingly, the density of
the band correlates well with the amount of virus injected (1.6× vs.
1×). When a specific antibody against SERCA2 was assayed, the right
band appeared in all heart samples (AdESERCA1-Kir2.1–injected and
control) with the same magnitude. GP, guinea pig. 
Figure 3
Intracellular Ca2+ transients. Representative Ca2+ transients elicited
in control (a) and AdESERCA1-Kir2.1–infected myocytes (b) are
shown. AdESERCA1-Kir2.1 infection increased the amplitude of the
Indo-1 fluorescence ratio. (c) Average data are summarized (n = 5 for
AdESERCA1-Kir2.1 group, and n = 8 for control). *P < 0.05, control
versus S-K group, t test.
tricle end-diastolic (LVED) and left ventricle end-sys-
tolic (LVES) dimensions and septal and left ventricle
free wall thickness were made. Heart rate was deter-
mined simultaneously with dimension measurements,
and shortening fraction was calculated using the for-
mula (LVED – LVES)/LVED.
Statistical analysis. Pooled data are presented as mean
± SEM. Comparisons between groups were performed
using t test to compare unpaired data or two-way
ANOVA to compare measurements made before and
after ectopic expression in the same animals. P values
less than 0.05 were deemed significant.
Results
Ectopic expression of SERCA1a protein in the infected hearts.
We first sought to verify the expression of SERCA1 pro-
tein after intramyocardial injection in the S-K group.
Western blot analysis was performed using cardiac
homogenates to detect SERCA1a protein expression.
Figure 2 shows that a SERCA1a-specific antibody (14)
detected a band (∼100 kDa) in the AdESERCA1-
Kir2.1–injected guinea pig hearts, but not in AdEGI-
injected animals, where only SERCA2 was evident. Cal-
cium transients. Cardiac myocytes isolated from humans
and from several animal models of heart failure typi-
cally exhibit intracellular Ca2+ transients with decreased
amplitudes (13, 16) consistent with decreased contrac-
tility, which is the hallmark of heart failure. The
SERCA2a in the heart normally maintains appropriate
Ca2+ loading of the sarcoplasmic reticulum (SR) , there-
by serving as a key modulator of releasable Ca2+ during
excitation-contraction coupling. Heart failure is gener-
ally associated with decreased Ca2+ loading of the SR,
so that supplementation of SERCA is a logical goal of
therapy to reverse contractile dysfunction (17). Here,
our primary goal was to preserve systolic function in
the face of the abbreviation of excitation by coex-
pressed K channels.
To determine the functional consequences of
SERCA1 ectopic expression in the absence of super-
imposed changes of excitability, we measured Ca2+
transients during depolarizing voltage steps in freshly
isolated cardiomyocytes from the left ventricle of
injected guinea pigs. The results, shown in Figure 3,
revealed a significant increase in the amplitude of
Indo-1 fluorescence ratios in the AdESERCA1-
Kir2.1–infected cells compared with control myocytes
(noninfected cells of the same hearts and AdEGI-
infected myocytes) (1.56 ± 0.14, n = 6, vs. 1.00 ± 0.12, 
n = 8; P < 0.05, t test). Thus, SERCA1 overexpression in
the bicistronic vector enhanced the availability of acti-
vator Ca2+, a functional effect which may be salutary
in heart failure and which would tend to offset the
effects of K channel overexpression. Note that these
calcium transients were deliberately measured under
voltage clamp, with identical voltage step durations
and amplitudes in both groups, to define changes of
calcium availability independent of any changes in
APD or morphology.
Overexpression of Kir2.1 protein. We next sought to ver-
ify the overexpression of Kir2.1 in the S-K group. Here,
we cannot take advantage of differentially specific anti-
bodies, as Kir2.1 is normally expressed in the ventricle.
Thus, we performed quantitative immunoblots using
an antibody against Kir2.1 protein and compared the
expression by densitometry to that of actin (which was
assumed not to change). An increase of expression was
detected in cardiac homogenates from AdESERCA1-
Kir2.1–infected hearts (Figure 4). Nevertheless, given
the uncertainties of interpreting relatively small per-
cent changes in immunoblots, we next sought func-
tional evidence of an increased density of inward recti-
fier K channels in cardiomyocytes from the S-K group.
Overexpression of IK1 in guinea pig myocytes. As shown in
Figure 5, 72 hours after injection and stimulation with
GS-E, freshly isolated infected myocytes from the S-K
group exhibit a significant increase in the inwardly rec-
tifying IK1 density. The increase is particularly evident
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Figure 4
Kir2.1 protein expression. (a) Western blot analysis using a poly-
clonal antibody against Kir2.1 protein. Although the specific band at
approximately 42 kDa was present in both samples, its density was
greater in the AdESERCA1-Kir2.1–injected guinea pig heart. (b) The
relative expression of Kir2.1 normalized per actin protein for the same
Western blot. Kir2.1 expression in the AdESERCA1-Kir2.1–injected
heart was 30% higher than in control.
Figure 5
Inward rectifier K current (IK1). AdESERCA1-Kir2.1–infected myocytes
showed a significant increase in IK1 amplitude at negative membrane
potentials when compared with control myocytes (AdEGI-infected or
noninfected cells). *P < 0.01, two-way ANOVA; n ≥ 8 for each point.
at negative membrane potentials where conductance is
large (i.e., –54.8 ± 3.8 pA/pF vs. –30.7 ± 3.6 pA/pF at
–140 mV, n = 8 for each group; P < 0.001, two-way
ANOVA). We tested the functional importance of
Kir2.1 overexpression at less negative potentials by
examining the effect of AdESERCA1-Kir2.1 infection
on AP repolarization.
APD. Prolongation of the AP is characteristic of ven-
tricular myocytes isolated from animals and humans
with heart failure (13, 18–21). Changes in the APD
result from alterations in the functional expression of
depolarizing and repolarizing currents that are active
during the plateau phase. Repolarization in the mam-
malian heart is achieved primarily by the activity of
potassium-selective ionic currents. IK1 contributes to
the terminal phase of repolarization, so an increase in
the expression of these channels is a logical mechanism
to shorten the APD. Figure 6 shows steady-state APs
stimulated at 1 Hz in freshly isolated control and S-K
ventricular myocytes at 37°C in the absence of added
calcium buffer to the cytosol. The SERCA-
Kir2.1–infected myocyte APs were significantly shorter
than control myocyte APs, at both 50% and 90% repo-
larization (188.8 ± 35.9 ms vs. 292.2 ± 15.6 ms [APD50]
and 220.1 ± 38.8 ms vs. 346.7 ± 18.6 ms [APD90], for 
S-K myocytes [n = 8] vs. for control cells [n = 13], respec-
tively; P < 0.05, t test).
We acknowledge that the electrophysiologic and Ca2+
handling pathways in the heart interact and, as such,
may have impacted the degree of AP abbreviation
achieved via genetic manipulation of SERCA1 and
Kir2.1 channels. We tested whether SERCA1 overex-
pression, by altering intracellular Ca2+ handling, had
potentially increased or decreased the effect of Kir2.1
overexpression on abbreviation of APD via Ca2+-
dependent modulation of membrane potential. Cellu-
lar AP recordings were made under identical condi-
tions, with one exception: the addition of the cytosolic
Ca2+ buffer EGTA (5 mM). By buffering the Ca2+ tran-
sient, we eliminated Ca2+-dependent modulation of
membrane potential exerted by the Ca2+-sensing
actions of the L-type Ca current, the electrogenic
Na+/Ca2+ exchange, and other Ca2+ actions on currents.
Under these Ca2+-buffered conditions, APs in control
cells (APD50 = 302.7 ± 82.8 ms, APD90 = 376.8 ± 79.8 
ms, n = 6) were slightly longer and APs in S-K cells 
(APD50 = 147.9 ± 28.9 ms, APD90 = 194.8 ± 22.5 ms, 
n = 5) were shorter on average compared with APs
recorded in the absence of any added Ca2+ buffer (not
significant). Thus, via this experimental assessment,
coexpression of SERCA1 moderated the impact of
Kir2.1-overexpressed channels to shorten the AP.
These data demonstrate the intended therapeutic
effect of overexpression of Kir2.1 at the cellular level. As
long as SERCA-Kir2.1 overexpression does not aggra-
vate contractile dysfunction, increased IK1 current
would be expected to reduce the incidence of ventricu-
lar arrhythmias in failing hearts, by stabilizing repolar-
ization and by suppressing triggered activity.
Widespread ectopic expression of SERCA1a protein. Prior
to performing cardiac function measurements, we ver-
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Figure 6
APD. (a and b) Representative action potentials elicited in control and AdESERCA1-Kir2.1–infected myocytes. AdESERCA1-Kir2.1 infection
abbreviated the AP. (c) Average APD50 and APD90 data are summarized (n = 8 for AdESERCA1-Kir2.1 group, and n = 13 for control). 
*P < 0.05, AdESERCA1-Kir2.1 versus control, t test.
Figure 7
Widespread SERCA1 expression. Western blots from two different
animals subjected to multiple-site injections of AdESERCA1-Kir2.1
throughout the left ventricle are shown. In both blots, the first lane
corresponds to a homogenate of guinea pig skeletal muscle as a pos-
itive control for the SERCA1a-specific mAb A52 (14). Lanes 2 and 3
are the samples of the right ventricle, and lanes 4–9 correspond to
each of six pieces into which the left ventricle was cut. Widespread
expression of ectopic SERCA1a protein (∼100-kDa band) was
obtained in the injected left ventricle, whereas no SERCA1a expres-
sion was observed in the noninjected right ventricle.
ified widespread expression of SERCA1a protein
throughout the left ventricle of animals that under-
went multiple-site injections of AdESERCA1-Kir2.1.
Western blot analysis was performed using
homogenates of right and left ventricle and the
SERCA1a-specific mAb A52 (14). The right ventricle
was sectioned into two samples (Figure 7, lanes 2 and
3) and the left ventricle was cut into six similarly sized
pieces (lanes 4–9). Figure 7 shows the Western blots
from two different animals 72 hours after injection. In
both blots, the first lane corresponds to a homogenate
of guinea pig skeletal muscle used as a positive control
for the antibody. Detection of the approximately 100-
kDa SERCA1a-specific band in the immunoblots doc-
uments that widespread expression of ectopic
SERCA1a protein was obtained throughout the entire
left ventricle (lanes 4–9) in one animal and in five of six
sections (lanes 4–8) of left ventricle in the other animal
in which Western blot analysis was performed to assess
the extent of protein expression. In contrast, no
SERCA1a expression was observed in the noninjected
right ventricle (lanes 2 and 3).
ECG recordings. Arrhythmias are a major cause of death
in heart failure (22, 23). Cardiomyocytes from failing
hearts reveal abnormalities in repolarization with pro-
longation of the QT interval, basically due to downreg-
ulation of K+ currents, that favor the devel-
opment of such arrhythmias. ECG
recordings were performed in animals that
had undergone widespread injection of the
adenovirus vectors into the left ventricular
myocardium. The QT interval was measured
and corrected for heart rate using the follow-
ing formula, with all measurements in sec-
onds: QTc = QT / √cyclelength.
As shown in Figure 8, the QTc interval
measured at 72 hours after injection and
stimulation with GS-E was significantly abbreviated in
the AdESERCA1-Kir2.1–injected guinea pigs com-
pared with measurements made in the same animal
immediately after surgery (0.26 ± 0.02 s vs. 0.36 ± 0.02 s;
P < 0.03, paired t test). In contrast, no changes in the
QTc interval were observed in the animals injected
with AdEGI (0.33 ± 0.01 s vs. 0.33 ± 0.03 s; not signifi-
cant). There was no difference, either, in the QTc inter-
val recorded immediately after surgery between the
two groups of animals (AdESERCA1-Kir2.1– and
AdEGI-injected; data not shown).
Cardiac echocardiography. Table 1 displays the data
from the cardiac echocardiography measurements.
There were no significant differences in the left ven-
tricular dimensions in the AdEGI versus the AdESER-
CA1-Kir2.1 animals. Left ventricular function as
assessed by shortening fraction was also highly similar
in the two groups. Heart rates were slightly higher,
though not significantly so in the AdESERCA1-Kir2.1
animals. The septal and left ventricle free wall thick-
nesses were also not significantly different between the
two groups (data not shown), indicating no patholog-
ic hypertrophy developed in the animals. Although the
AdESERCA1-Kir2.1 animals had significantly short-
ened APD and QT intervals, the function was not
impaired, perhaps due to increased SR pumping effi-
ciency related to the SERCA1 overexpression.
Discussion
To our knowledge, this is the first study to demonstrate
the general utility of combination gene therapy for the
heart, where both genes may be “therapeutic” and one
is designed to offset the potentially adverse effects of the
other. With the ultimate goal of normalizing the cardiac
rhythm and increasing myocardial contractility in fail-
ing hearts without increasing vulnerability to arrhyth-
mia, we created a dual gene therapy vector that  coex-
presses the skeletal muscle calcium ATPase isoform
SERCA1 and the inward rectifier K channel Kir2.1. We
hypothesized that overexpression of Kir2.1 alone would
accelerate terminal repolarization but at the expense of
contractility. Additional overexpression of SERCA1
would offset the loss of contractility due to abbreviation
of the AP. In myocyte experiments, we have abbreviated
APD and enhanced SR Ca2+ reuptake without creating
unphysiologic or proarrhythmic effects. In vivo, we have
abbreviated QT interval without impairing contractili-
ty. This research provides proof of principle that in vivo
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Figure 8
ECG analysis: QTc interval. A significant reduction was observed in
the QTc interval in AdESERCA1-Kir2.1–injected animals (black bars).
No changes occurred in the animals treated with AdEGI. *P = 0.003,
immediately after surgery versus 72 hours after injection and stimu-
lation with GS-E, paired t test.
Table 1
Echocardiography measurements in guinea pigs 72 hours after viral injection
LVED LVES SF Cycle length Heart rate
(cm) (cm) (%) (s) (beats/min)
AdEGI Mean 0.733 0.498 32.3 0.204 296
SE 0.033 0.038 2.8 0.008 13
AdESERCA1 Mean 0.738 0.512 30.7 0.192 310
-Kir2.1 SE 0.043 0.036 2.1 0.0034 6
t test P value 0.937 0.806 0.67 0.244 0.366
K channel gene transfer can modify cardiac repolariza-
tion without undermining contractility, a combination
that may be useful as antiarrhythmic therapy.
The current analysis is limited to characterizing the
acute effects of transgene expression. Whether endoge-
nous gene expression is altered by acute overexpression
of SERCA1 and Kir2.1 or by overexpression-induced
alterations in myocyte function was not probed in this
study. For example, we do not know if these types of
genetic manipulations induce potential downstream
stress or hypertrophic responses, which may become
important considerations in the design of future
chronic gene transduction studies.
Why not monogenic therapy? Solo gene therapy strate-
gies, based upon selective overexpression of a single
gene, may not suffice to treat multifactorial diseases
such as heart failure. It is the interplay between the
electrical and contractile components of heart failure
that confounds the design of successful monogenic
treatments. Our early results with novel antiarrhyth-
mic monogenic gene therapy, based upon manipula-
tion of a select K channel gene and targeted to correct
the electrical abnormalities alone, adversely impacted
contractility (1), which is already depressed in heart
failure. In our earliest study, we expressed a noninacti-
vating Shaker potassium channel (ShK) in ventricular
myocytes isolated from cardiomyopathic adult canine
hearts (1). A low level of ShK expression reversed the
abnormal phenotype of the failing myocyte by short-
ening APD sufficiently to modify the failing AP wave-
form to resemble closely that of the normal myocytes
(1). Moderate and higher levels of ShK expression
abbreviated the failing AP markedly and reduced the
size of contractions in AdShK-infected cells (Figure 1).
In general, shortenings in AdShK-infected cells became
smaller as the level of expressed ShK current increased
and were roughly half as large as in control cells (1). At
the highest levels of ShK expression achieved, APs were
so severely modified that excitation was effectively
uncoupled from contraction. In the present study, we
have shown that a K channel gene and an SR Ca2+
ATPase gene can be overexpressed in tandem to offset
the contractile depression associated with monogenic
K channel overexpression.
Rationalizing global effects on repolarization. One paradox
in the current work is the ability to observe global cor-
relates of transduction (QT interval abbreviation),
while the proportion of GFP-positive isolated myocytes
is relatively low (2–3% based upon visual assessments
of myocytes isolated from single-site-injected hearts).
Several considerations help to resolve this paradox.
First, multiple sites (∼ 10) in the heart were injected
(once per site) in the experiments designed to assess
ECGs and echocardiograms whereas only a single site
was infiltrated (albeit several times) when the sole
objective was the isolation of myocytes for electro-
physiological study . Second, the proportion of trans-
duced myocytes may have been underestimated by our
insistence on selecting only those cells that exhibited
bright green fluorescence, which would have excluded
cells that had taken up and expressed lower levels of the
viral constructs. Third, it should be recognized that the
heart is an electrical syncytium, and that the electrical
effects of transduction will be felt as far away as approx-
imately 1 mm or more from any given injected cell due
to electrotonic effects through low-resistance gap junc-
tions (24, 25) Thus, relatively low, conservative esti-
mates of transduction efficiency after myocyte iso-
lation are not necessarily incompatible with modi-
fication of global repolarization in vivo.
Our successful modification of cardiac excitability
and contractility of the normal heart in vivo using dual
gene therapy will motivate our future efforts to offset
electrical and contractile abnormalities of common
acquired forms of heart disease and to prevent fatal
arrhythmias. This type of dual gene therapy can be gen-
eralized to exploit opposing or synergistic therapeutic
principles to achieve a tailored phenotype.
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